凯利泰(300326) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥294.40 million, a decrease of 7.29% compared to ¥317.55 million in the same period last year[8]. - The net profit attributable to shareholders was ¥74.90 million, down 0.78% from ¥75.49 million year-on-year[8]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥46.51 million, a significant decline of 36.25% from ¥72.96 million in the previous year[8]. - Total operating revenue for Q1 2023 was CNY 294,401,832.83, a decrease of 7.27% compared to CNY 317,546,846.50 in Q1 2022[33]. - Net profit for Q1 2023 was CNY 75,078,222.16, a decline of 1.76% from CNY 76,423,135.11 in Q1 2022[34]. - Total comprehensive income for Q1 2023 was CNY 65,202,506.86, a decrease from CNY 73,320,376.69 in Q1 2022, representing a decline of approximately 8.3%[35]. Cash Flow - The net cash flow from operating activities increased by 23.34% to ¥76.51 million, compared to ¥62.04 million in the same period last year[8]. - Net cash flow from operating activities was CNY 76,514,802.08, an increase of 23.4% compared to CNY 62,035,512.25 in the same period last year[38]. - Total cash inflow from operating activities was 357.18 million, a slight increase of 0.35% from 355.94 million[23]. - Total cash outflow from operating activities decreased by 4.51% to 280.66 million, down from 293.91 million[23]. - Total cash outflow from operating activities was CNY 280,662,503.31, down from CNY 293,905,340.25 in the previous year, indicating improved cash management[38]. - Cash inflow from financing activities increased by 36.84% to 26.51 million, compared to 19.38 million last year[24]. - Cash inflow from financing activities was CNY 26,514,161.43, compared to CNY 19,376,473.22 in the same period last year, reflecting increased financing efforts[38]. - Cash outflow from financing activities surged by 76.24% to 77.69 million, up from 44.08 million[24]. - The company incurred a total of CNY 185,000,000.00 in cash outflow related to investment activities, consistent with the previous year's CNY 185,790,000.00[38]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3.40 billion, a slight decrease of 0.32% from ¥3.41 billion at the end of the previous year[8]. - Total assets as of Q1 2023 amounted to CNY 3,401,111,783.56, slightly down from CNY 3,412,148,611.26 at the end of the previous quarter[31]. - Total liabilities decreased to CNY 524,828,835.39 from CNY 597,447,117.66 in the previous year, reflecting a reduction of 12.14%[31]. - The equity attributable to shareholders of the parent company increased to CNY 2,800,973,334.40 from CNY 2,739,569,604.96, representing a growth of 2.24%[31]. Investment Income - The company reported an investment income of ¥30.02 million from equity swaps, contributing positively to the financial results[11]. - Investment income recognized was 30.02 million due to the fair value difference from the equity swap of Ligetai and Yiting Medical[23]. - The company reported an investment income of CNY 29,188,157.40, a significant recovery from a loss of CNY 2,005,772.10 in the previous year[34]. Other Income and Expenses - The company's other income increased by 336.62% to ¥297.99 million, indicating improved performance in this area[21]. - The orthopedic consumables manufacturing business faced significant adverse impacts due to the implementation of centralized procurement policies, leading to a decline in sales revenue and gross margin[11]. - The company experienced a 50.91% reduction in employee compensation liabilities, reflecting payments made for previously accrued salaries and bonuses[14]. - The company's financial expenses decreased significantly by 109.39% to -¥22.97 million, attributed to reduced interest expenses and increased interest income[21]. - Research and development expenses decreased to CNY 13,021,152.19, down 18.19% from CNY 15,916,371.28 in the same period last year[34]. - Other comprehensive income after tax for Q1 2023 was CNY -9,875,715.30, compared to CNY -3,102,758.42 in Q1 2022, indicating a worsening in this area[34]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 54,605[26]. - The largest shareholder, Yongjin Investment Holdings, holds 6.99% of shares, totaling 50.1 million shares[26]. Cash and Cash Equivalents - The company's cash and cash equivalents decreased to 659.64 million from 707.49 million at the beginning of the year[29]. - Cash and cash equivalents at the end of the period stood at CNY 654,769,877.61, up from CNY 620,967,187.64 at the end of Q1 2022[38]. - The company's cash and cash equivalents were not explicitly stated but are part of the total current assets of CNY 1,801,550,584.30[31]. Audit Status - The report was not audited, indicating that the figures are preliminary and subject to change[39].